Rituximab and Subcutaneous 2-Chloro-2′-Deoxyadenosine as Therapy in Untreated and Relapsed Waldenström's Macroglobulinemia
Authors:
- D LaszloDLD Laszlo
- G AndreolaGAG Andreola
- L RigacciLRL Rigacci
- A FabbriAFA Fabbri
- C RabascioCRC Rabascio
- A PintoAPA Pinto
- M NegriMNM Negri
- G MartinelliG Martinelli
- 1 February 2011
- journal article
- research article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 11 (1) , 130-132
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- International prognostic scoring system for Waldenström macroglobulinemiaBlood, 2009
- Increased Incidence of Transformation and Myelodysplasia/Acute Leukemia in Patients With Waldenström Macroglobulinemia Treated With Nucleoside AnalogsJournal of Clinical Oncology, 2009
- Fludarabine, Cyclophosphamide and Rituximab in Waldenström’s Macroglobulinemia: An Effective Regimen Requiring a New Category of Response Criteria and a Delayed Assessment of ResultsBlood, 2007
- Update on treatment recommendations from the Third International Workshop on Waldenstrom's MacroglobulinemiaBlood, 2006
- Guidelines on the management of Waldenström macroglobulinaemia*British Journal of Haematology, 2006
- Waldenström’s Macroglobulinemia: Clinical Features, Complications, and ManagementJournal of Clinical Oncology, 2000
- Cladribine (2‐CDA) given as subcutaneous bolus injections is active in pretreated Waldenström's macroglobulinaemiaBritish Journal of Haematology, 1997